Appeal 2007-0856
Application 09/281,474
the compound has a linking group of a specified formula between the
targeting moiety and chelator. The Examiner correctly points out that the
linking group recited in claim 1 can simply be, for example, O, S, C(=O), or
an amino acid, where g, g’, k, h’, g’’, h’’, and g’’’ are all zero, as they can be
(Answer 11).1
Claims 52 and 53 read as follows:
52. A compound comprising a peptide or peptidomimetic αvβ3 receptor
targeting moiety bound to a chelator.
53. A compound, comprising a peptide or peptidomimetic αvβ3 receptor
targeting moiety bound to a chelator, wherein said chelator is a
diaminedithiol, monoamine-monoamidedithiol, triamide-monothiol,
monoamine-diamide-monothiol, diaminedioxime, hydrazine, or cyclic
polyaminocarboxylate, or acyclic polyaminocarboxylate.
2. REFERENCES
The Examiner relies on the following references:
Palladino US 5,780,426 Jul. 14, 1998
Sharma US 6,331,285 B1 Dec. 18, 2001
Harris US 6,511,648 B2 Jan. 28, 2003
Cheesman US 6,558,649 B1 May 6, 2003
3. OBVIOUSNESS
Claims 1, 2, 12-15, 17, 19-21, 25, 27, 28, 31-35, 48-50, 52, and 53
stand rejected under 35 U.S.C. § 103 as obvious over Palladino in view of
Sharma. The Examiner relies on Palladino for disclosing “peptides that may
be used to treat diseases involving αvβ3 receptors,” including cancer and
1 In fact, when s, s’, s’’, t, and t’ are also 0, it is unclear whether claim 1
requires a linking group at all.
4
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
Last modified: September 9, 2013